<DOC>
	<DOC>NCT00299494</DOC>
	<brief_summary>The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.</brief_summary>
	<brief_title>Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Subjects with CD20 and CD22positive, follicular or diffuse large Bcell NHL who have not responded or progressed after 1 or 2 prior therapies; or subjects with CD20 and CD22positive intermediate/aggressive NHL (diffuse large Bcell, mantle cell, transformed follicular or follicular grade 3b NHL) who have not responded or progressed after 1 or more prior therapies and are refractory to a previous rituximab containing therapy. Prior therapy must contain at least one course of rituximab therapy, as single agent or in combination. Measurable disease. Subjects who are candidates for other potentially curative therapies. Subjects must not have received previous radioimmunotherapy. Subjects who have undergone a prior bone marrow transplantation within the last 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>